Lisata Therapeutics, Inc. (LSTA)

Lisata Therapeutics, Inc. (LSTA) Healthcare & Pipeline Overview

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in cellular therapies, with a focus on developing and commercializing innovative treatments for critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease. The company's pipeline includes promising candidates in Phase II clinical trials.

What Is the Investment Thesis for LSTA?

Lisata Therapeutics presents a high-risk, high-reward investment profile characteristic of clinical-stage biopharmaceutical companies. The company's valuation is approximately $40 million. Key to its success is the progression of its lead candidates, HONEDRA and XOWNA, through clinical trials. Positive Phase II results for HONEDRA in critical limb ischemia and XOWNA in coronary microvascular dysfunction could serve as significant catalysts, driving substantial value appreciation. The SAKIGAKE designation for HONEDRA in Japan offers a potential fast track to market approval in a key geographic region. However, the company's negative profit margin of -9756.5% underscores its reliance on future clinical and commercial success. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's ability to secure additional funding to support its operations. The high beta of 1.11 indicates greater volatility compared to the broader market.

Based on FMP financials and quantitative analysis

LSTA Key Highlights

• Market capitalization of $30.69M reflects its small-cap status and growth potential.
• Gross margin of 91.2% indicates strong pricing power for its therapies, if approved.
• HONEDRA's SAKIGAKE designation in Japan could expedite regulatory approval and market access.
• Phase II clinical trials for HONEDRA and XOWNA represent near-term catalysts for potential value creation.
• The company operates with 26 employees, indicating a lean and focused operational structure.

Who Are LSTA's Competitors?

LSTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LSTA's Key Strengths?

• Proprietary cellular therapy platform.
• Pipeline of clinical-stage assets.
• SAKIGAKE designation for HONEDRA.
• Experienced management team.

What Are LSTA's Weaknesses?

• Limited financial resources.
• High reliance on clinical trial success.
• Negative profit margin.
• Small number of employees.

What Could Drive LSTA Stock Higher?

• Phase II clinical trial results for HONEDRA in critical limb ischemia.
• Phase IIb clinical trial results for XOWNA in coronary microvascular dysfunction.
• Regulatory interactions with the FDA and other agencies.
• Potential for strategic collaborations and partnerships.

What Are the Key Risks for LSTA?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for HONEDRA, XOWNA, or CLBS201.
• Regulatory delays or rejection of marketing applications.
• Competition from other companies developing cellular therapies.
• Difficulty securing additional funding to support operations.
• Intellectual property challenges or patent infringement claims.

What Are the Growth Opportunities for LSTA?

• Expansion into new therapeutic areas: Lisata could leverage its expertise in cellular therapies to expand its pipeline into new therapeutic areas beyond its current focus. The regenerative medicine market is projected to reach $55.8 billion by 2028, offering ample opportunities for growth. This expansion could involve developing therapies for other cardiovascular diseases, neurological disorders, or autoimmune conditions. A successful expansion would diversify the company's risk profile and create new revenue streams.
• Geographic expansion: Lisata's current focus is primarily on the US and Japanese markets. Expanding into other regions, such as Europe and Asia-Pacific, could significantly increase its market reach. The global biotechnology market is expected to reach $3.87 trillion by 2030, with Asia-Pacific being the fastest-growing region. Establishing partnerships or subsidiaries in these regions could facilitate market entry and accelerate growth.
• Strategic collaborations and partnerships: Lisata could pursue strategic collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its therapies. These partnerships could provide access to funding, expertise, and distribution networks. The pharmaceutical industry is increasingly relying on collaborations to drive innovation and reduce risk. A successful partnership could significantly enhance Lisata's competitive position and accelerate its growth trajectory.
• Advancing clinical trial programs: The successful completion of Phase II clinical trials for HONEDRA and XOWNA is critical for Lisata's growth. Positive results would pave the way for Phase III trials and eventual regulatory approval. The market for critical limb ischemia and coronary microvascular dysfunction is significant, with limited treatment options available. Securing regulatory approval for these therapies would generate substantial revenue and establish Lisata as a leader in these therapeutic areas.
• Acquisition of complementary technologies: Lisata could acquire companies or technologies that complement its existing pipeline and expertise. This could involve acquiring companies with novel drug delivery systems, advanced cell manufacturing capabilities, or promising preclinical assets. The biotechnology industry is characterized by frequent mergers and acquisitions, as companies seek to expand their capabilities and market share. A strategic acquisition could enhance Lisata's competitive advantage and accelerate its growth.

What Opportunities Does LSTA Have?

• Expansion into new therapeutic areas.
• Strategic collaborations and partnerships.
• Geographic expansion.
• Positive clinical trial results.

What Threats Does LSTA Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from larger pharmaceutical companies.
• Difficulty securing funding.

What Are LSTA's Competitive Advantages?

• Proprietary cellular therapy technologies.
• SAKIGAKE designation for HONEDRA in Japan.
• Clinical trial data demonstrating efficacy.
• Strong intellectual property portfolio.

What Does LSTA Do?

Lisata Therapeutics, Inc., established in 1980 and headquartered in Basking Ridge, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing cellular therapies. The company's mission centers on reversing disease progression and promoting the regeneration of damaged tissues through innovative therapeutic approaches. Lisata's lead product candidates include HONEDRA, which has received SAKIGAKE designation and is currently in Phase II clinical trials for the treatment of critical limb ischemia (CLI). CLI is a severe form of peripheral artery disease that reduces blood flow to the extremities. Another key asset is XOWNA, which is in Phase IIb clinical trials for the treatment of coronary microvascular dysfunction (CMVD), a condition affecting the small blood vessels of the heart. Additionally, CLBS201, a CD34+ cell therapy, is being developed for pre-dialysis patients with chronic kidney disease (CKD). The company was initially incorporated as NeoStem, Inc., later changing its name to Caladrius Biosciences, Inc. in June 2015, before ultimately rebranding as Lisata Therapeutics, Inc. on September 15, 2022. This evolution reflects the company's strategic shift and focus on advancing its cellular therapy pipeline. Lisata operates with a team of 26 employees, managed by CEO David J. Mazzo, and is committed to addressing unmet medical needs in areas with limited treatment options.

What Products and Services Does LSTA Offer?

• Develops cellular therapies to reverse disease.
• Promotes regeneration of damaged tissue.
• Focuses on critical limb ischemia with HONEDRA.
• Targets coronary microvascular dysfunction with XOWNA.
• Treats pre-dialysis patients with chronic kidney disease using CLBS201.
• Conducts Phase II clinical trials for HONEDRA and XOWNA.

How Does LSTA Make Money?

• Develops and patents cellular therapy technologies.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA.
• Commercializes approved therapies through sales and marketing.

What Industry Does LSTA Operate In?

Lisata Therapeutics operates within the biotechnology sector, which is characterized by high innovation, long development cycles, and significant regulatory hurdles. The market for cellular therapies is growing, driven by advancements in regenerative medicine and personalized healthcare. Competition is intense, with both large pharmaceutical companies and smaller biotechs vying for market share. Lisata's focus on critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease positions it in areas of unmet medical need, offering potential for significant market penetration if its therapies prove effective and safe. The company's success will depend on its ability to navigate the complex regulatory landscape, secure funding, and differentiate its products from existing and emerging therapies.

Who Are LSTA's Key Customers?

• Patients suffering from critical limb ischemia.
• Patients with coronary microvascular dysfunction.
• Pre-dialysis patients with chronic kidney disease.
• Healthcare providers and hospitals.

Company Profile

Lisata Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Basking Ridge, US. The company is led by CEO David J. Mazzo. LSTA has traded publicly since 1999.

F-Score 1/9Financial Health

Lisata Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Key Financial Metrics

Its free cash flow yield is -44.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -53.7%, the inverse of the P/E and a quick read on earnings relative to price.

LSTA Valuation & Market Position

With a $30.69M market cap, Lisata Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, LSTA's quantitative score of 18/100 is below the peer average of 76/100.

FY2026 estForward Outlook

Wall Street analysts project Lisata Therapeutics, Inc. revenue of about $135K for fiscal 2026, with EPS near $-1.09.

LSTA Financials

LSTA Latest News

LSTA Analyst Consensus

LSTA MoonshotScore

Latest Lisata Therapeutics, Inc. Analysis

Common Questions About LSTA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources